The Italy-based company says its Vertiva platform now covers 10mL volumes. It plans to present the latest Vertiva development at CPhI Milan next month.
Vertiva features a single-use injection unit (or pod) and a multi-use smart controller. They communicate through a patented magnetically coupled drive mechanism. The interlocked pod contains a pre-filled glass cartridge, either in 3mL or 10mL format, loaded into the pod during factory assembly. This results in a ready-to-use device benefitting patients with simplified, safe and comfortable treatment initiation at home.
“We are excited to announce that the Vertiva platform represents a significant breakthrough for the biopharma industry,” said Stevanato Group VP of Business Line DDS, Michele Monico. “By combining sustainable and modular design with versatile delivery capabilities, the move to larger volume capacity extends treatment options for a wider range of therapies, enabling biopharma companies to faster and lower cost stability and clinical evaluations. This advancement will redefine how we approach patient at-home and on-body treatment, paving the way for more adaptable and patient-centered solutions.”
More about the Stevanato Group Vertiva platform
Users have the option to have their controller record data on usage and transfer it via Bluetooth to digital health applications, too. Stevanato Group says its two-part design enables easy separation of the reusable controller from the disposable pod at treatment completion. This significantly reduces the environmental impact of electronic components and improves overall device sustainability.
Stevanato Group said Vertiva can be pre-programmed to accommodate different motor-driven dosing profiles, too. That ranges from micro-precision basal delivery to full-content bolus injections. This enables the administration of a wide range of small molecule and biologic therapies for treating conditions such as cardiovascular and metabolic disorders, oncology, immunology, and pain diseases.
Last year, the company announced plans to bring this on-body device to market through a collaboration with Thermo Fisher Scientific. The companies plan to offer the platform as an integrated device and fill-and-finish solution. Stevanato Group then unveiled the Vertiva system in June 2023.
